Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma

Drugs

Volumn 71, Issue 10, 2011, Pages 1233-1250

  Natarajan, Nagendra ^a   Telang, Sucheta ^a   Miller, Donald ^a   Chesney, Jason ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Cisplatin; CP 870893; Dabrafenib; Dacarbazine; Denileukin diftitox; Granulocyte macrophage colony stimulating factor; Imatinib; Interferon alpha 2b; Interleukin 2; Ipilimumab; MAGE A3 peptide vaccine; MDX 1106; PD 325901; Selumetinib; Sorafenib; Talminogene laherparepvec; Temozolomide; Trametinib; Tremelimumab; Ureluma; Vemurafenib; Vinblastine.

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE INHIBITOR; CISPLATIN; CP 870893; DABRAFENIB; DACARBAZINE; DENILEUKIN DIFTITOX; GLYCOPROTEIN GP 100; GSK 2118436; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; IPILIMUMAB; MDX 1106; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA2B; PLACEBO; PROTEIN KINASE INHIBITOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RO 5185426; SORAFENIB; TEMOZOLOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; URELUMAB; VELIMOGENE ALIPLASMID; VEMURAFENIB; VINBLASTINE;

ANTIGEN PRESENTING CELL; ARTHRALGIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CAPILLARY LEAK SYNDROME; CHEMOTHERAPY INDUCED EMESIS; CHILL; COLITIS; COMBINATION CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LOOSE FECES; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOCYTE DEPLETION; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; RIGOR; SIDE EFFECT; SKIN; SKIN CARCINOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYNCOPE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; SURVIVAL;

HUMAN HERPESVIRUS 1;

EID: 79960501416     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11591380-000000000-00000     Document Type: Review

References (121)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin 2010 Sep-Oct; 60 (5): 277-300.
2. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001 Aug 15; 19 (16): 3635-48. (Pubitemid 32786276)
3. Eggermont AM, Voit C. Management of melanoma: a European perspective. Surg Oncol Clin N Am 2008 Jul; 17 (3): 635-48, x. (Pubitemid 351699254)
4. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005 Feb 19; 365 (9460): 687-701. (Pubitemid 40260892)
5. Boon T, Coulie PG, Van den Eynde BJ, et al. cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
6. Aptsiauri N, Cabrera T, Garcia-Lora A, et al. MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol 2007; 256: 139-89. (Pubitemid 46109029)
7. Mendez R, Rodriguez T, Del Campo A, et al. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 2008 May; 57 (5): 719-29. (Pubitemid 351641032)
8. Cabrera T, Lara E, Romero JM, et al. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007 May; 56 (5): 709-17. (Pubitemid 46348739)
9. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6 (1): 34-55. (Pubitemid 32155814)
10. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996 Jan; 14 (1): 7-17. (Pubitemid 26019991)
11. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000 Jun; 18 (12): 2444-58. (Pubitemid 30415832)
12. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon formelanoma. Clin Cancer Res 2004 Mar 1; 10 (5): 1670-7. (Pubitemid 38435557)
13. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005 Oct 1; 366 (9492): 1189-96. (Pubitemid 41393597)
14. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008 Jul 12; 372 (9633): 117-26. (Pubitemid 351952257)
15. Linsley PS, Brady W, Grosmaire L, et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991 Mar 1; 173 (3): 721-30.
16. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007 Dec 15; 110 (12): 2614-27. (Pubitemid 350250330)
17. Tivol EA, Borriello F, SchweitzerAN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995 Nov; 3 (5): 541-7.
18. Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006 Apr; 18 (2): 206-13. (Pubitemid 43327304)
19. Bristol-Myers Squibb. Efficacy study of ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanoma [ClinicalTrials.gov identifier: NCT00636168]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
20. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colonystimulating factor. J Exp Med 1992 Dec 1; 176 (6): 1693-702.
21. Xu Y, Zhan Y, Lew AM, et al. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol 2007 Dec 1; 179 (11): 7577-84.
22. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993 Apr 15; 90 (8): 3539-43. (Pubitemid 23111402)
23. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000 Apr; 18 (8): 1614-21. (Pubitemid 30220539)
24. Lawson DH, Lee SJ, Tarhini AA, et al. E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma [abstract no. 8504]. J Clin Oncol 2010; 28 Suppl. 15: 8504.
25. Kim KB, Legha SS, Gonzalez R, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 2009 Feb; 19 (1): 42-9.
26. James Graham Brown Cancer Center. Adjuvant, combined interleukin 2 (proleukin) and DTIC (dacarbazine) in highrisk melanoma patients [ClinicalTrials.gov identifier: NCT00553618]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 Jun 23].
27. Bilsborough J, Panichelli C, Duffour MT, et al. AMAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens 2002 Jul; 60 (1): 16-24. (Pubitemid 35177020)
28. BreckpotK,Heirman C, De Greef C, et al. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol 2004 Feb 15; 172 (4): 2232-7. (Pubitemid 38182371)
29. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994 Mar 1; 179 (3): 921-30. (Pubitemid 24065650)
30. Herman J, van der Bruggen P, Luescher IF, et al. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 1996; 43 (6): 377-83. (Pubitemid 26099398)
31. Kawashima I, Hudson SJ, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998 Jan; 59 (1): 1-14. (Pubitemid 28141258)
32. Kruit WH, Suciu S, Dreno B, et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group (16032-18031) [abstract]. J Clin Oncol 2008; 26 Suppl. 15: 9065.
33. GlaxoSmithKline. A phase III study to test the benefit of a new kind of anti-cancer treatment in patients with melanoma, after surgical removal of their tumor [ClinicalTrials.gov identifier: NCT00796445]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 Jun 23].
34. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008 Mar-Apr; 58 (2): 71-96. (Pubitemid 351521864)
35. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008 Feb 1; 26 (4): 527-34. (Pubitemid 351264344)
36. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988 May 27; 240 (4856): 1169-76.
37. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999 Jul; 17 (7): 2105-16. (Pubitemid 29318842)
38. Novartis Pharmaceuticals. Aldesleukin in patients with metastatic renal cell carcinoma and metastatic melanoma [ClinicalTrials.gov identifier: NCT00414765]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
39. Slingluff Jr CL, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001 Oct; 7 (10): 3012-24. (Pubitemid 32963818)
40. Schwartzentruber DJ, Lawson D, Richards J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364 (22): 2119-27.
41. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998 May; 16 (5): 1752-9. (Pubitemid 28234719)
42. McDermott DF, Mier JW, Lawrence DP, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res 2000 Jun; 6 (6): 2201-8. (Pubitemid 30399185)
43. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008 Dec 10; 26 (35): 5748-54.
44. Hamm C, Verma S, Petrella T, et al. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 2008 Apr; 34 (2): 145-56.
45. Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007 Dec 1; 25 (34): 5426-34. (Pubitemid 350232219)
46. O'Day SJ, Atkins MB, Boasberg P, et al. Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma. J Clin Oncol 2009 Dec 20; 27 (36): 6207-12.
47. Moroz A, Eppolito C, Li Q, et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004 Jul 15; 173 (2): 900-9. (Pubitemid 38924263)
48. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000 Nov 2; 408 (6808): 57-63.
49. Parrish-Novak J, Foster DC, Holly RD, et al. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002 Nov; 72 (5): 856-63. (Pubitemid 35365159)
50. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007 Jan 15; 178 (2): 732-9. (Pubitemid 46095145)
51. Davis ID, Skrumsager BK, Cebon J, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007 Jun 15; 13 (12): 3630-6. (Pubitemid 46955126)
52. Petrella R, Tozer K, Belanger KJ, et al. Interleukin-21 (IL-21) activity in patients with metastic melanoma [abstract no. 8507]. J Clin Oncol 2010; 28 Suppl. 15: 8507.
53. NCIC Clinical Trials Group. A randomized phase II study of interleukin-21 (rIL-21) versus dacarbazine (DTIC) in patients with metastatic or recurrent melanoma [ClinicalTrials. gov identifier: NCT01152788]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 Jun 23].
54. Dubois S, Patel HJ, Zhang M, et al. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008 Feb 15; 180 (4): 2099-106.
55. EpardaudM, Elpek KG, Rubinstein MP, et al. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008 Apr 15; 68 (8): 2972-83. (Pubitemid 351556298)
56. National Cancer Institute. A phase I study of intravenous recombinant human IL-15 in adults with refractory metastatic malignant melanoma and metastatic renal cell cancer [ClinicalTrials.gov identifier: NCT01021059]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
57. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2009; 11 (2): 155-64.
58. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (8): 711-23.
59. Robert S, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. Epub 2011 Jun 5.
60. Eggermont AM, Suciu S, Rutkowski P, et al. Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961 [abstract]. J Clin Oncol 2010; 28 Suppl. 15: 8505.
61. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2011; 107 (9): 4275-80.
62. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007 Jul; 27 (1): 111-22. (Pubitemid 47089023)
63. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007 Jul; 19 (7): 813-24. (Pubitemid 47241890)
64. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28 (19): 3167-75.
65. Bristol-Myers Squibb.Dose-escalation study of combination BMS-936558 (MDX-1106) and ipilimumab in subjects with unresectable stage III or stage IV malignant melanoma [ClinicalTrials.gov identifier: NCT01024231]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
66. H. Lee Moffitt Cancer Center and Research Institute. Monoclonal antibody therapy and vaccine therapy in treating patients with stage IV melanoma that has been removed by surgery [ClinicalTrials.gov identifier: NCT01176474]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
67. H. Lee Moffitt Cancer Center and Research Institute. Vaccine therapy and monoclonal antibody therapy in treating patients with stage III or stage IV melanoma that cannot be removed by surgery [ClinicalTrials.gov identifier: NCT01176461]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
68. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000 Jan; 67 (1): 2-17. (Pubitemid 30046812)
69. von Leoprechting A, van der Bruggen P, Pahl HL, et al. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocytemediated lysis and induces apoptosis. Cancer Res 1999 Mar 15; 59 (6): 1287-94. (Pubitemid 29136260)
70. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007 Mar 1; 25 (7): 876-83. (Pubitemid 350002889)
71. Abramson Cancer Center of the University of Pennsylvania. Tremelimumab and CP-870,893 in patients with metastatic melanoma [ClinicalTrials.gov identifier: NCT01103635]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
72. Shao Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol 2011; 89 (1): 21-9.
73. Sun Y, Chen JH, Fu Y. Immunotherapy with agonistic anti-CD137: two sides of a coin. Cell Mol Immunol 2004 Feb; 1 (1): 31-6.
74. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer [abstract]. J Clin Oncol 2008; 26 Suppl.: 3007.
75. Bristol-Myers Squibb. Phase II, 2nd line melanoma-RAND monotherapy [ClinicalTrials.gov identifier: NCT00612664]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
76. Gonzalez R, Hutchins L, Nemunaitis J, et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006 Dec; 16 (6): 521-6. (Pubitemid 44934710)
77. Vical. A phase 3 pivotal trial comparing Allovectin-7 alone vs chemotherapy alone in patients with stage 3 or stage 4 melanoma [ClinicalTrials.gov identifier: NCT00395070]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
78. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003 Feb; 10 (4): 292-303. (Pubitemid 36305598)
79. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colonystimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009 Dec 1; 27 (34): 5763-71.
80. BioVex Limited. Efficacy and safety study of oncoVEXGMCSF compared to GM-CSF in melanoma [ClinicalTrials. gov identifier: NCT00769704]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
81. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008 Nov 10; 26 (32): 5233-9.
82. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res. Epub 2011 May 11.
83. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009 Jul 16; 114 (3): 535-46.
84. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006 Oct 6; 314 (5796): 126-9. (Pubitemid 44547756)
85. Hong JJ, Rosenberg SA, Dudley ME, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010; 16 (19): 4892-8.
86. Jones E, Dahm-Vicker M, Golgher D, et al. CD25+ regulatory T cells and tumor immunity. Immunol Lett 2003 Jan 22; 85 (2): 141-3. (Pubitemid 36071568)
87. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005 Apr 1; 105 (7): 2862-8. (Pubitemid 40446280)
88. Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002 Feb 22; 2: 1.
89. Turk MJ, Guevara-Patino JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004 Sep 20; 200 (6): 771-82. (Pubitemid 39299463)
90. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004 Jul 15; 173 (2): 1444-53. (Pubitemid 38924326)
91. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005 Feb 15; 105 (4): 1640-7. (Pubitemid 40223685)
92. Rasku MA, Clem AL, Telang S, et al. Transient T cell depletion causes regression of melanoma metastases. J TranslMed 2008 Mar 11; 6 (1): 1-18.
93. Chesney J, Rasku M, Klarer AC, et al. Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma. J Clin Oncol 2011; 29 Suppl.: 2507.
94. Eisai Inc. Study of ONTAK in patients with stage IIIC and stage IV melanoma [ClinicalTrials.gov identifier: NCT01127451]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 Jun 23].
95. Avruch J,KhokhlatchevA,Kyriakis JM, et al.Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001; 56: 127-55.
96. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002 Jun 27; 417 (6892): 949-54. (Pubitemid 34716871)
97. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006 Sep 4; 95 (5): 581-6. (Pubitemid 44325897)
98. McDermott DF, Sosman JA, Gonzalez R, et al. Doubleblind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008 May 1; 26 (13): 2178-85.
99. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363 (9): 809-19.
100. Sosman J, Kim K, Schuchter LM, et al. An open-label, multicenter phase II study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma [abstract 30] Pigment Cell Melanoma Res 2010. 23 Suppl.: 912.
101. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. Epub 2011 Jun 5.
102. Kefford RF, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract]. J Clin Oncol 2010; 28 Suppl. 15: 8503.
103. GlaxoSmithKline. A study comparing GSK2118436 to dacarbazine (DTIC) in previously untreated subjects with BRAF mutation positive advanced (stage III) or metastatic (stage IV) melanoma [ClinicalTrials.gov identifier: NCT01227889]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
104. Poulikakos PI, Rosen N. Mutant BRAF melanomas: dependence and resistance. Cancer Cell 2011; 19 (1): 11-5.
105. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364 (8): 772-4.
106. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK orN-RAS upregulation. Nature 2010; 468 (7326): 973-7.
107. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468 (7326): 968-72.
108. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18 (6): 683-95.
109. Haass NK, Sproesser K, Nguyen TK, et al. The mitogenactivated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 2008 Jan 1; 14 (1): 230-9. (Pubitemid 351378000)
110. Banerji U, Camidge DR, Verheul HM, et al. The first-inhuman study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16 (5): 1613-23.
111. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16 (6): 1924-37.
112. Thompson DS, Flaherty KT, Messersmith W, et al. A three-part, phase I, dose escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma. J Clin Oncol 2009; 27 Suppl.: e14584.
113. GlaxoSmithKline. Investigate safety, pharmacokinetics and pharmacodynamics of GSK2118436 & GSK1120212 [ClinicalTrials.gov identifier: NCT01072175]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 23].
114. Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010; 29 (41): 5545-55.
115. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008 Sep 2; 99 (5): 734-40.
116. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005 Apr 25; 92 (8): 1398-405. (Pubitemid 40705006)
117. Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006 May 1; 106 (9): 2005-11. (Pubitemid 43673217)
118. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010; 102 (8): 1219-23.
119. Fisher DE, Barnhill R, Hodi FS, et al. Melanoma from bench to bedside: meeting report from the 6th International Melanoma Congress. Pigment Cell Melanoma Res 2010; 23 (1): 14-26.
120. Clem BF, Clem AL, Yalcin A, et al. A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene. Epub 2011 Mar 21.
121. Yalcin A, Clem B, Makoni S, et al. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene 2010; 29 (1): 139-49